Immuneering (IMRX) Change in Account Payables (2020 - 2026)
Immuneering (IMRX) recorded quarterly Change in Account Payables of -$89579.0 in Q1 2026, down 222.02% quarter-over-quarter from $73415.0 in Q4 2025, and up 86.98% on a YoY basis from -$47909.0 in Q1 2025.
Immuneering (IMRX) Change in Account Payables (2020 - 2026) Analysis & Trends
Immuneering's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$89579.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 86.98% year-over-year to -$89579.0; the TTM figure through Mar 2026 stood at $197493.0 (up 121.53% YoY), while the FY2025 annual figure was -$400799.0, down 257.4% from the prior year.
- Change in Account Payables was -$89579.0 for Q1 2026 at Immuneering, down from $73415.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q2 2025 to a low of -$974893.0 in Q3 2025.
- Historically, Change in Account Payables has averaged $2988.2 across 5 years, with a median of $56741.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables tumbled 731.07% in 2022, then surged 675.42% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $816177.0 in 2022, then plunged by 79.1% to $170568.0 in 2023, then tumbled by 66.73% to $56741.0 in 2024, then gained by 29.39% to $73415.0 in 2025, then slumped by 222.02% to -$89579.0 in 2026.
- The last three Change in Account Payables figures came in at -$89579.0 (Q1 2026), $73415.0 (Q4 2025), and -$974893.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | -89,579.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89,579.00 |
| Mar 31, 2026 | -89,579.00 |
| Dec 31, 2025 | 73,415.00 |
| Dec 31, 2025 | 73,415.00 |
| Sep 30, 2025 | -974,893.00 |
| Sep 30, 2025 | -974,893.00 |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | -687,871.00 |
| Mar 31, 2025 | -687,871.00 |
| Dec 31, 2024 | 56,741.00 |
| Dec 31, 2024 | 56,741.00 |
| Sep 30, 2024 | -679,454.00 |
| Sep 30, 2024 | -679,454.00 |
| Jun 30, 2024 | 393,177.00 |
| Jun 30, 2024 | 393,177.00 |
| Mar 31, 2024 | 117,393.00 |
| Mar 31, 2024 | 117,393.00 |
| Dec 31, 2023 | 170,568.00 |
| Dec 31, 2023 | 170,568.00 |